Intensive Session Examines the State of Precision Medicine
The rapidly-evolving field of precision medicine is poised to make a critical impact on cardiovascular care. Today, a special intensive, co-chaired by Rhonda M. Cooper-DeHoff, PharmD, MS, FACC, a member of ACC’s Cardiovascular Team Section Leadership Council, and Douglas L. Mann, MD, FACC, editor-in-chief of JACC: Basic to Translational Science, will look at the latest developments in the field, including the U.S. Food and Drug Administration’s (FDA’s) efforts to lead the way in the science of precision medicine.
The session, the last of ACC.16’s four intensives, will start with a discussion of President Obama’s Precision Medicine Initiative by Sekar Kathiresan, MD. The initiative, which is funded with a $215 million investment in the President’s 2016 budget, will “pioneer a new model of patient-powered research that promises to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients,” according to the White House.
For an even closer look at the present and future of precision medicine, FDA Commissioner Robert M. Califf, MD, MACC, will present “Precision Medicine: Where Does the FDA Stand?” In December 2015, the FDA launched precisionFDA, a web platform that allows scientists from a number of backgrounds to collaborate on the science behind a method of “reading” DNA known as next-generation.
“Precision medicine is not just a project; it is the way of the future for the FDA, optimizing the use of genetics, genomics, biological measurements, electronic health records, wearable devices and environmental data to define effective foods, drugs, devices and biologics that improve health and treat disease,” explains Califf.
Attendees will also hear discussion of genotype testing and dosing of various pharmaceuticals, pharmacogenetics and genomics, and tools for clinical practice, along with several case-based discussions.
< Back to Listings